TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28356241

Group type: EXPERIMENTAL
Intervention: 3D VR intervention using Samsung Gear Oculus VR headset
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2D distraction video on a 14-inch bedside screen (Control)
Number of subjects: 100
Study: 28356275

Group type: EXPERIMENTAL
Intervention: Konjac glucomannan, a viscous soluble fiber, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28356278

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28356282

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose (LD)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg loading dose (LD)
Number of subjects: 2
Study: 28356426

Group type: EXPERIMENTAL
Intervention: Whole-grain intake as reflected by dietary records and biomarkers
Number of subjects: 0
Study: 28356432

Group type: EXPERIMENTAL
Intervention: Diet with inflammatory potential
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28356440

Group type: EXPERIMENTAL
Intervention: Revascularization for coronary artery stenosis with a low FFR (≤0.75)
Number of subjects: 5846

Group type: COMPARATOR
Intervention: Deferred lesions with FFR measurement
Number of subjects: 5846

Group type: COMPARATOR
Intervention: Medical treatment for stenosis with a high FFR (≥0.76)
Number of subjects: 5846
Study: 28357679

Group type: EXPERIMENTAL
Intervention: Veterans RAND 12-Item Health Survey (VR-12) - Physical Component Summary (PCS)
Number of subjects: 7902

Group type: EXPERIMENTAL
Intervention: Veterans RAND 12-Item Health Survey (VR-12) - Mental Component Summary (MCS)
Number of subjects: 7902

Group type: EXPERIMENTAL
Intervention: Global assessment measure for quality of life
Number of subjects: 7902

Group type: EXPERIMENTAL
Intervention: Overall VR-12 score
Number of subjects: 7902

Group type: EXPERIMENTAL
Intervention: Orthopedic surgery
Number of subjects: 7902

Group type: EXPERIMENTAL
Intervention: Gastrointestinal/hepatobiliary or urologic surgery
Number of subjects: 7902
Study: 28357727

Group type: EXPERIMENTAL
Intervention: BEZ235 (dactolisib) at doses of 200, 400, and 800 mg daily along with everolimus at 2.5 mg daily in 28-day cycles
Number of subjects: 19
Study: 28357772

Group type: EXPERIMENTAL
Intervention: Once-daily injected GLP1 agonist lixisenatide (Lixi) and basal insulin analogue glargine (iGlar)
Number of subjects: 9
Study: 28358734

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 19
Study: 28359201

Group type: EXPERIMENTAL
Intervention: Adjunctive Vagus Nerve Stimulation (VNS)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 795
Study: 28359318

Group type: EXPERIMENTAL
Intervention: Combined targeted therapy bevacizumab and erlotinib (BE)
Number of subjects: 43
Study: 28359411

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study: 28360015

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (145 mg/m2)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 733
Study: 28360208

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28360242

Group type: EXPERIMENTAL
Intervention: Northern Shanghai Risk Score calculation based on CV risk factors and TODs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical examination, anthropometric measurement, and questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up assessments every 2 years
Number of subjects: 0
Study: 28360250

Group type: EXPERIMENTAL
Intervention: Brussels Infant and Toddler Stool Scale (BITSS)
Number of subjects: 0
Study: 28360259

Group type: EXPERIMENTAL
Intervention: Patients with HFpEF (n=22)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Patients without HFpEF (n=12)
Number of subjects: 34
Study: 28360853

Group type: EXPERIMENTAL
Intervention: Dance intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Walking intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Walking + Nutrition intervention
Number of subjects: 174

Group type: COMPARATOR
Intervention: Active Control (stretching and toning)
Number of subjects: 174
Study: 28361390

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate pretreatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oxytocin 10
Number of subjects: 26
Study: 28361468

Group type: EXPERIMENTAL
Intervention: PSP users (participated in the patient support program)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: PSP non-users (did not participate in the patient support program)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: PSP users
Number of subjects: 1025
Study: 28363153

Group type: EXPERIMENTAL
Intervention: Ureido-substituted benzenesulfonamides (USBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLC-0111/U-F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hCA II (off-target) and hCA IX-mimic (target)
Number of subjects: 0
Study: 28363360

Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed influenza diagnosis
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Other respiratory viruses
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Co-infection with influenza and another respiratory virus
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Influenza virus types
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Direct medical costs associated with laboratory-confirmed influenza
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Vaccine administration
Number of subjects: 501
Study: 28363483

Group type: EXPERIMENTAL
Intervention: Intracortical brain-computer interface (iBCI) with functional electrical stimulation (FES)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Virtual arm control
Number of subjects: 1
Study: 28363682

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) during PCI-S
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-low bleeding risk group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-low bleeding risk category
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy
Number of subjects: 0
Study: 28363725

Group type: EXPERIMENTAL
Intervention: Anaesthesia procedures
Number of subjects: 30874
Study: 28363827

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Combination of predictive parameters (DAS28, IFN score, DMARD use)
Number of subjects: 226
Study: 28363920

Group type: EXPERIMENTAL
Intervention: Combined piped water and sanitation intervention
Number of subjects: 90
Study: 28364045

Group type: EXPERIMENTAL
Intervention: T1 mapping
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 73

Group type: COMPARATOR
Intervention: T2-weighted short tau inversion recovery (T2W-STIR)
Number of subjects: 73
Study: 28364198

Group type: EXPERIMENTAL
Intervention: Medium sedation using propofol TCI
Number of subjects: 43
Study: 28364214

Group type: EXPERIMENTAL
Intervention: Robust patients
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Frail patients
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Pre-frail patients
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Robust patients receiving chemotherapy
Number of subjects: 1280
Study: 28364368

Group type: EXPERIMENTAL
Intervention: User fees for GP consultations
Number of subjects: 343
Study: 28364381

Group type: EXPERIMENTAL
Intervention: Adalimumab with Methotrexate (MTX)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Adalimumab with low-dose MTX (<8 mg/week)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Adalimumab with high-dose MTX (≥8 mg to ≤16 mg/week)
Number of subjects: 157
Study: 28364451

Group type: EXPERIMENTAL
Intervention: Higher protein intake on BL1 and BL2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate intake on BL1 and BL2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Greater fat-free mass
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Higher body fat percentage
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Being overweight (BMI 25-30)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Greater fiber consumption on BL1 and BL2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake the following day (BL2)
Number of subjects: 50
Study: 28364479

Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring during weaning from CPB
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Normal myocardial function classification via accelerometer
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) stroke work and systolic velocity by echocardiography
Number of subjects: 23
Study: 28364495

Group type: EXPERIMENTAL
Intervention: Sexsomnia patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sleepwalkers
Number of subjects: 17
Study: 28364869

Group type: EXPERIMENTAL
Intervention: TX-004HR (low-dose 17β-estradiol vaginal softgel capsule)
Number of subjects: 0
Study: 28365080

Group type: EXPERIMENTAL
Intervention: Nutrition therapy (NT)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (CT)
Number of subjects: 351
Study: 28365204

Group type: EXPERIMENTAL
Intervention: 12-week home-based training with body-controlled videogames
Number of subjects: 10
Study: 28366306

Group type: EXPERIMENTAL
Intervention: l-arginine infusion
Number of subjects: 22
Study: 28366342

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (0.5, 1, 2, 3 mg/24 h) applied daily and up-titrated weekly.
Number of subjects: 24
Study: 28366441

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mapping biopsies
Number of subjects: 112

Group type: COMPARATOR
Intervention: High-definition white-light (HD-WL) endoscopy
Number of subjects: 112
Study: 28367260

Group type: EXPERIMENTAL
Intervention: Intradermal injection of Botulinum Toxin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of Botulinum Toxin A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28357039

Group type: EXPERIMENTAL
Intervention: Intensive practice
Number of subjects: 0
Study: 28367334

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (Spin)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonaerobic exercise control (Balance)
Number of subjects: 32
Study: 28367426

Group type: EXPERIMENTAL
Intervention: MSCs implantation (20-50×10^6 MSCs)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MSCs implantation
Number of subjects: 5
Study: 28368443

Group type: EXPERIMENTAL
Intervention: Continuous kisspeptin infusion (12.5 µg/kg/h) over 24 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Kisspeptin (0.313 µg/kg) and GnRH (75 ng/kg) intravenous boluses
Number of subjects: 8
Study: 28368516

Group type: EXPERIMENTAL
Intervention: ORIGIN biomarker panel
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: hsTnI levels
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: ORIGIN biomarkers
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: hsTnI levels added to ORIGIN models
Number of subjects: 350
Study: 28368743

Group type: EXPERIMENTAL
Intervention: IV VRC01 (10, 20, 30 or 40 mg/kg) every 4 or 8 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SC VRC01 (5 mg/kg) every 2 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 10 mg/kg 8-weekly regimen
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 30 mg/kg 8-weekly regimen
Number of subjects: 84
Study: 28369210

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 106
Study: 28369303

Group type: EXPERIMENTAL
Intervention: TAo-first
Number of subjects: 301

Group type: COMPARATOR
Intervention: TAo-last
Number of subjects: 301
Study: 28369329

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously (IV) every 4 weeks
Number of subjects: 68
Study: 28369341

Group type: EXPERIMENTAL
Intervention: Intraduodenal fecal microbiota transplantation (FMT)
Number of subjects: 20
Study: 28369415

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (all doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: In vitro tenofovir-dp formation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide dosing in vivo
Number of subjects: 24
Study: 28369553

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 24
Study: 28370090

Group type: EXPERIMENTAL
Intervention: Terlipressin plus albumin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo plus albumin
Number of subjects: 308
Study: 28370350

Group type: EXPERIMENTAL
Intervention: Daclatasvir/asunaprevir/beclabuvir (DCV-TRIO) 30 mg, 200 mg, and 75 mg respectively, administered twice daily for 12 weeks.
Number of subjects: 169
Study: 28370444

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 481
Study: 28370677

Group type: EXPERIMENTAL
Intervention: Olfactory function assessment using Sniffin' Sticks Extended Test in MCI individuals
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Olfactory identification score in MCI individuals
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (FMD) assessment in MCI individuals
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study: 28371297

Group type: EXPERIMENTAL
Intervention: Nutritional intervention program 'DiOGenes'
Number of subjects: 473
Study: 28372575

Group type: EXPERIMENTAL
Intervention: Systematic assessment of respiratory mechanics (bedside measurements)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Post-assessment ventilator settings
Number of subjects: 61
Study: 28372865

Group type: EXPERIMENTAL
Intervention: Obese adolescents
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal-weight adolescents
Number of subjects: 20
Study: 28373005

Group type: EXPERIMENTAL
Intervention: Avelumab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity
Number of subjects: 184
Study: 28373007

Group type: EXPERIMENTAL
Intervention: Avelumab 1 mg/kg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Avelumab 3 mg/kg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Avelumab 20 mg/kg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Avelumab (all doses)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg and 20 mg/kg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Avelumab (3 mg/kg and 10 mg/kg)
Number of subjects: 53
Study: 28373069

Group type: EXPERIMENTAL
Intervention: Crizotinib therapy
Number of subjects: 1669
Study: 28373243

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance at baseline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up scans at 6 months postpartum
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Death/transplant rates at 12 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline cardiovascular magnetic resonance scans
Number of subjects: 100
Study: 28373258

Group type: EXPERIMENTAL
Intervention: Hospitalised patients with intra-abdominal infection, pneumonia, complicated urinary tract infections, and bloodstream infections caused by CRE
Number of subjects: 202

Group type: COMPARATOR
Intervention: Patients with carbapenem-susceptible infections (matched control group)
Number of subjects: 202
Study: 28373262

Group type: EXPERIMENTAL
Intervention: Ibrutinib at a once-daily dose of 420 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (lower dose intensity)
Number of subjects: 0
Study: 28373269

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (<120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard blood pressure control (<140 mm Hg)
Number of subjects: 9361
Study: 28373849

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 0
Study: 28374214

Group type: EXPERIMENTAL
Intervention: Medicaid coverage for diabetes cohort
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Medicaid coverage for hypertension cohort
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Medicaid coverage for hyperlipidemia cohort
Number of subjects: 1998
Study: 28374496

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Entecavir hydrate (ETV) 0.5 mg
Number of subjects: 166
Study: 28375658

Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin single-pill combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empagliflozin or linagliptin as first-line treatment
Number of subjects: 0
Study: 28375789

Group type: EXPERIMENTAL
Intervention: 0.15% preservative-free zinc-hyaluronate
Number of subjects: 20
Study: 28375876

Group type: COMPARATOR
Intervention: Bone conduction hearing aid + NH condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CI + NH condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: NH-alone condition
Number of subjects: 20
Study: 28376109

Group type: COMPARATOR
Intervention: NAFLD
Number of subjects: 320

Group type: COMPARATOR
Intervention: Metabolic Syndrome (MetS)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: LECT2 levels
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Quartiles of LECT2 levels
Number of subjects: 320
Study: 28376316

Group type: EXPERIMENTAL
Intervention: Nadroparin added to chemotherapy
Number of subjects: 477
Study: 28376728

Group type: EXPERIMENTAL
Intervention: RNA-seq on fresh-frozen (FF) specimens
Number of subjects: 21

Group type: COMPARATOR
Intervention: RNA-seq on formalin-fixed paraffin-embedded (FFPE) specimens
Number of subjects: 21
Study: 28376739

Group type: EXPERIMENTAL
Intervention: Seroprevalence of Bordetella pertussis antibodies in adults
Number of subjects: 0
Study: 28376791

Group type: EXPERIMENTAL
Intervention: Normalization of maximal CCA wall thickness to median IMT
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Higher CCA thickness parameter values
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ratio of wall thickness and diameter
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Normalization of maximal wall thickness to end-diastolic diameter
Number of subjects: 240
Study: 28376799

Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 69
Study: 28376837

Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Number of subjects: 50
Study: 28376908

Group type: EXPERIMENTAL
Intervention: SAPS II score
Number of subjects: 5266

Group type: EXPERIMENTAL
Intervention: SAPS 3 score
Number of subjects: 5266
Study: 28377399

Group type: EXPERIMENTAL
Intervention: Ex vivo models of DBA
Number of subjects: 0
Study: 28377958

Group type: EXPERIMENTAL
Intervention: 10 or 25 μg vitamin D supplementation
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 28378429

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (change in diet and cardiovascular fitness)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (change in diet)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Increased sweetened beverage intake
Number of subjects: 699
Study: 28378544

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole orally once daily for 8 days
Number of subjects: 24
Study: 28378561

Group type: EXPERIMENTAL
Intervention: Multiple-pinhole (MPH) glasses
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single-pinhole (SPH) glasses
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both MPH and SPH glasses
Number of subjects: 36
Study: 28378918

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 64
Study: 28379370

Group type: EXPERIMENTAL
Intervention: Initial Specimen Diversion Device (ISDD)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Standard phlebotomy procedures
Number of subjects: 904
Study: 28379401

Group type: EXPERIMENTAL
Intervention: Asymmetric wall thickening detected by magnetic resonance
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Asymmetric wall thickening detected by echocardiography
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Increased cardiac troponin I and brain natriuretic peptide concentrations
Number of subjects: 166
Study: 28379421

Group type: EXPERIMENTAL
Intervention: Increased baseline BMI
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: BMI increase by 3 and 5 years
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Higher baseline BMI in pre-menopausal endocrine therapy trial MA.12
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Increased BMI in pre-menopausal endocrine therapy trial MA.12
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Baseline BMI in post-menopausal endocrine therapy trials MA.14 and MA.27
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Mean increased BMI of 0.3 in post-menopausal endocrine therapy trials MA.14 and MA.27
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Baseline BMI and BMI change in trastuzumab administration
Number of subjects: 2793
Study: 28379427

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg once daily subcutaneously for 21 days
Number of subjects: 10
Study: 28379580

Group type: EXPERIMENTAL
Intervention: Long-term lifestyle intervention
Number of subjects: 330
Study: 28379878

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 24